These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10605710)

  • 41. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J; Hudecek J; Kubisz P
    Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Proceedings: Congenital deficiency of factors XI and XII].
    Vaccari A
    Minerva Pediatr; 1973 Dec; 25(42):1929-32. PubMed ID: 4774589
    [No Abstract]   [Full Text] [Related]  

  • 43. Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency.
    Boffa MB
    J Thromb Haemost; 2016 Aug; 14(8):1600-2. PubMed ID: 27279430
    [No Abstract]   [Full Text] [Related]  

  • 44. Biologic activities of the contact factors in vivo--potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis.
    Colman RW
    Thromb Haemost; 1999 Dec; 82(6):1568-77. PubMed ID: 10613636
    [No Abstract]   [Full Text] [Related]  

  • 45. Factor XI and platelets: activation and regulation.
    Walsh PN; Baglia FA; Jameson BA
    Thromb Haemost; 1993 Jul; 70(1):75-9. PubMed ID: 8236119
    [No Abstract]   [Full Text] [Related]  

  • 46. A novel factor XI gene mutation associated with mild factor XI deficiency in a symptomatic patient.
    Ramadan KM; McNulty O; Anderson JA; Jones FG; Winter PC
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):499-502. PubMed ID: 16905957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Four novel FXI gene mutations in three factor XI- deficient patients.
    de Raucourt E; de Mazancourt P; Quélin F
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):240-2. PubMed ID: 18388506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies on the clot-promoting effect of skin.
    Ogston D; Ogston CM; Ratnoff OD
    J Lab Clin Med; 1969 Jan; 73(1):70-7. PubMed ID: 5762166
    [No Abstract]   [Full Text] [Related]  

  • 49. [Activation system of fibrinolysis (author's transl)].
    Okamoto U
    Rinsho Ketsueki; 1974 Aug; 15(8):827-39. PubMed ID: 4613880
    [No Abstract]   [Full Text] [Related]  

  • 50. [Study and clinical significance of the fibrinolysis component dependent on factor XIIa].
    Arkhipov AG; Eremin GF
    Lab Delo; 1985; (11):648-51. PubMed ID: 2417013
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of factor XI in coagulation.
    Broze GJ; Gailani D
    Thromb Haemost; 1993 Jul; 70(1):72-4. PubMed ID: 8236118
    [No Abstract]   [Full Text] [Related]  

  • 52. Factor XI, much more than an innocent observer.
    Camelo-Castillo A; Marín F; Roldán V
    J Thromb Haemost; 2020 Dec; 18(12):3172-3173. PubMed ID: 33467843
    [No Abstract]   [Full Text] [Related]  

  • 53. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.
    Weiss AS; Gallin JI; Kaplan AP
    J Clin Invest; 1974 Feb; 53(2):622-33. PubMed ID: 11344577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Factor XI deficiency caused by a mutation of Gly400Val].
    Sato T; Iyama S; Araki N; Murase K; Sato Y; Kobune M; Takimoto R; Matsunaga T; Kato J; Kuroda H; Niitsu Y
    Rinsho Ketsueki; 2007 Feb; 48(2):148-50. PubMed ID: 17370644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
    Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency.
    Spena S; Asselta R; Caccia S; Rimoldi V; Giacomelli SH; Tagliaferri A; Peyvandi F; Castaman G; Duga S
    Thromb Haemost; 2009 Sep; 102(3):603-6. PubMed ID: 19718484
    [No Abstract]   [Full Text] [Related]  

  • 57. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy.
    Salomon O; Steinberg DM; Seligshon U
    Haemophilia; 2006 Sep; 12(5):490-3. PubMed ID: 16919078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of five novel mutations in the factor XI gene (F11) of patients with factor XI deficiency.
    Quélin F; Mathonnet F; Potentini-Esnault C; Trigui N; Peynet J; Bastenaire B; Guillon L; Bigel ML; Sauger A; Mazurier C; de Mazancourt P
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):69-73. PubMed ID: 16607084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel factor XI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild type II factor XI deficiency.
    Bozzao C; Rimoldi V; Asselta R; Landau M; Ghiotto R; Tenchini ML; De Cristofaro R; Castaman G; Duga S
    FEBS J; 2007 Dec; 274(23):6128-38. PubMed ID: 17971173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of combined factor VII and factor XI deficiencies.
    Quélin F; De Raucourt E; Mathonnet F; Tétégan M; Peltier JY; De Mazancourt P
    Haemophilia; 2008 May; 14(3):639-42. PubMed ID: 18248411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.